RecruitingInterventional · Phase 1NCT02074839 ↗A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
RecruitingInterventional · Phase 1NCT03816345 ↗A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)Ashish SaxenaPIInterventionProcedure: Biospecimen Collection · Drug: Cabozantinib · Drug: Fluoropyrimidine · Biological: Ipilimumab · Biological: Nivolumab · Drug: Platinum Compound · Drug: Platinum DoubletDatesJul 2019 – Mar 2028 (est.)SponsorNational Cancer InstituteAutoimmune DiseaseCrohn DiseaseDermatomyositis+11 more
Active, not recruitingInterventional · Phase 1/2NCT04067336 ↗A Phase 1/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: Ziftomenib · Drug: Midazolam · Drug: ItraconazoleDatesSep 2019 – Oct 2028 (est.)SponsorKura OncologyAdvanced Malignant NeoplasmAcute Myeloid LeukemiaMixed Lineage Leukemia+4 more
Active, not recruitingInterventional · Phase 2NCT04395222 ↗A Prospective Study of Tocilizumab for the Prevention of Graft Failure and Graft-versus-Host Disease in Haplo-Cord TransplantationAlexandra Gomez ArteagaPIInterventionDrug: Tocilizumab · Drug: Fludarabine · Drug: Melphalan · Drug: Anti-thymocyte globulin (rabbit) · Radiation: Total Body IrradiationDatesOct 2020 – Sep 2022· Results postedSponsorWeill Medical College of Cornell UniversityHematologic MalignancyBone Marrow Transplant
RecruitingInterventional · Not applicableNCT04515810 ↗Planning Advance Care Together (PACT) to Improve Engagement in Advance Care PlanningMegan Johnson ShenPIInterventionOther: Internet-Based Intervention · Other: Best Practice · Other: Telephone-Based Intervention · Other: Questionnaire Administration · Other: Post-intervention qualitative feedback interviewDatesFeb 2025 – May 2027 (est.)SponsorWeill Medical College of Cornell UniversityLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Hematologic Malignancy+1 more
Active, not recruitingInterventional · Phase 1/2NCT04730258 ↗Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMMLGail J RobozPIInterventionDrug: CFI-400945 · Drug: AzacitidineDatesApr 2021 – Jan 2026 (est.)SponsorTreadwell Therapeutics, Inc.Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+3 more
RecruitingInterventional · Phase 1NCT05735184 ↗Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination With Ziftomenib or Standard Induction Cytarabine/Daunorubicin (7+3) Chemotherapy in Combination With Ziftomenib for the Treatment of Patients With Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine · Drug: Daunorubicin · Drug: Cytarabine · Drug: QuizartinibDatesJul 2023 – Apr 2030 (est.)SponsorKura OncologyAcute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more
RecruitingInterventional · Phase 1NCT06001788 ↗Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: Ziftomenib · Drug: Fludarabine · Drug: Idarubicin · Drug: Cytarabine · Drug: Gilteritinib · Biological: Granulocyte colony-stimulating factorDatesFeb 2024 – Dec 2026 (est.)SponsorKura OncologyAMLAML With Mutated NPM1Hematologic Malignancy+9 more
RecruitingInterventional · Phase 1/2NCT06119685 ↗Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersMateo Mejia SaldarriagaPIInterventionDrug: IDP-023 · Drug: Rituximab · Drug: Daratumumab · Drug: Interleukin-2 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Mesna · Drug: IsatuximabDatesOct 2023 – Dec 2025 (est.)SponsorIndapta Therapeutics, Inc.NHLMultiple MyelomaBlood Cancer+4 more
RecruitingInterventional · Phase 3NCT06401356 ↗An Open-Label, Multicenter, Extension Study for Patients Previously Enrolled in Studies With PelabresibJoseph M ScanduraPIInterventionDrug: PelabresibDatesAug 2024 – Jun 2027 (est.)SponsorConstellation PharmaceuticalsHematologic MalignancySolid TumorAdvanced Malignancies
RecruitingInterventional · Phase 3NCT07007312 ↗Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: Ziftomenib · Drug: Placebo · Drug: Venetoclax · Drug: Azacitidine (AZA) · Drug: Daunorubicin · Drug: Cytarabine (Ara-C)DatesSep 2025 – Nov 2031 (est.)SponsorKura OncologyAcute Myeloid Leukemia (AML)
RecruitingInterventional · Phase 2NCT07216443 ↗A Phase 2 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeAlexandra Gomez ArteagaPIInterventionBiological: Orca-TDatesDec 2025 – Nov 2027 (est.)SponsorOrca BiosystemsLeukemia, Myeloid, AcuteMyelodysplastic SyndromesMixed Phenotype Acute Leukemia
TerminatedInterventional · Phase 3NCT02999854 ↗A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic MalignancySebastian A. MayerPIInterventionBiological: ATIR101 · Drug: Cyclophosphamide · Procedure: T-cell depleted HSCT from a related, haploidentical donor · Procedure: T-cell replete HSCT from a related, haploidentical donorDatesNov 2017 – Nov 2021· Results postedSponsorKiadis PharmaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
TerminatedInterventional · Phase 1NCT03248479 ↗A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological MalignanciesEllen K. RitchiePIInterventionDrug: Magrolimab · Drug: AzacitidineDatesSep 2017 – Sep 2023· Results postedSponsorForty Seven, Inc.Hematological Malignancies
CompletedInterventional · Phase 1NCT03555955 ↗A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic MalignanciesGail J RobozPIInterventionDrug: CPX-351DatesNov 2018 – May 2021SponsorJazz PharmaceuticalsHematologic MalignancyAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+2 more
CompletedInterventional · Phase 1NCT03787498 ↗A Phase 1b Dose-escalation Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic SyndromeGail J RobozPIInterventionDrug: PLX2853DatesMar 2019 – Jun 2021SponsorPlexxikon, Inc.Relapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)
TerminatedInterventional · Phase 4NCT04673175 ↗A Pilot Study of Ceftolozane-Tazobactam in Conjunction With Rapid Molecular Diagnosis for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell TransplantationMarkus PlatePIInterventionDrug: Ceftolozane / Tazobactam InjectionDatesJan 2023 – Mar 2025· Results postedSponsorWeill Medical College of Cornell UniversityPneumoniaHematologic MalignancyPseudomonas Aeruginosa Infection+2 more
CompletedInterventional · Phase 1/2NCT06179511 ↗A Modular Phase I/II, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD9829 as Monotherapy or in Combination in Patients With CD123-Positive Hematological MalignanciesPinkal DesaiPIInterventionDrug: AZD9829DatesJan 2024 – Oct 2025SponsorAstraZeneca, PLCHematological Malignancies